ATN 161

Drug Profile

ATN 161

Alternative Names: Ac-PHSCN-NH2

Latest Information Update: 05 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Attenuon LLC
  • Developer Attenuon; Tactic Pharma
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha 5 beta 1 inhibitors; Integrin alphaVbeta3 antagonists; Integrin alphaVbeta5 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glioma; Renal cancer

Most Recent Events

  • 04 Feb 2016 Discontinued - Phase-I/II for Glioma (Recurrent) in USA (IV) before February 2016
  • 04 Feb 2016 Discontinued - Phase-II for Renal cancer in USA (IV) before February 2016
  • 31 May 2008 No development reported - Phase-I/II for Glioma (Recurrent) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top